Showing 1931-1940 of 2192 results for "".
- LUCIDITY Clinical Trial Demonstrates Reduction of Plasma Biomarker Neurofilament Light Chain in Alzheimer Disease Participantshttps://practicalneurology.com/news/lucidity-clinical-trial-demonstrates-reduction-of-plasma-biomarker-neurofilament-light-chain-in-alzheimer-disease-participants/2470247/Results from the LUCIDITY clinical trial (NCT03446001) measuring the efficacy of hydromethylthionine mesylate (HMTM; TauRx, Singapore, Singapore) treatment for individuals with mild to moderate Alz
- Habitually Taking Daytime Naps Associated with Larger Total Brain Volumehttps://practicalneurology.com/news/habitually-taking-daytime-naps-associated-with-larger-total-brain-volume/2470229/According to research published in Sleep Health, people who habitually took daytime naps had brains that were larger by a volume equivalent to 2.6 to 6.5 years of aging compared to people who didn’t nap. The fi
- Study Evaluates Stigma of High-Frequency Headache/Migraine with Acute Medication Overdose as a Factor of Age, Gender, Employment Status, and Race/Ethnicityhttps://practicalneurology.com/news/study-evaluates-stigma-of-high-frequency-headachemigraine-with-acute-medication-overdose-as-a-factor-of-age-gender-employment-status-and-raceethnicity/2470213/Stigma associated with high-frequency headache/migraine with acute medication overdose (HFM+AMO) is more prevalent in employed, non-Hispanic Black male patients aged 18-49 years, according to a new study presented at the 65
- FDA to Hold Advisory Committee Meeting to Discuss Potential Stem Cell Therapy for ALShttps://practicalneurology.com/news/fda-to-hold-advisory-committee-meeting-to-discuss-potential-stem-cell-therapy-for-als/2470210/BrainStorm Cell Therapeutics Inc (New York, NY) announced that the Food and Drug Administration (FDA) will hold a meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (AdCOM) on September 27, 2023, to consi
- Hispanic/Latino Patients Experience MS Onset Earlier than White Participants, New Research Suggestshttps://practicalneurology.com/news/hispaniclatino-patients-experience-ms-onset-earlier-than-white-participants-new-research-suggests/2470201/According to research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), the age at onset (AAO) of multiple sclerosis (MS) was on average 5 years earlier for Hispanic/Latino patient
- Study Assesses the Quality of Life and Unmet Needs of Geriatric and Advanced MS Patientshttps://practicalneurology.com/news/study-assesses-the-quality-of-life-and-unmet-needs-of-geriatric-and-advanced-ms-patients/2470195/A study performed by members of the Medical College of Wisconsin analyzed quality of life (QOL) and rates of depression of patients with advanced multiple sclerosis (A-MS) and geriatric MS (G-MS) compared with younger patie
- FDA Grants Fast Track Designation to Factor XIa Inhibitor Milvexian to Treat Stroke, ACS, and AFhttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-factor-xia-inhibitor-milvexian-to-treat-stroke-acs-and-af/2470191/The investigational factor XIa (FXIa) inhibitor milvexian (Janssen Pharmaceuticals, Johnson & Johnson, Beerse, Belgium; Bristol Myers Squibb, New York, NY) was granted Fast Track designation by the Food and Drug Adminis
- First Treatment for Genetic Form of Amyotrophic Lateral Sclerosis Approved by FDAhttps://practicalneurology.com/news/first-treatment-for-genetic-form-of-amyotrophic-lateral-sclerosis-approved-by-fda/2470172/The Food and Drug Administration (FDA) approved the first treatment for amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. Tofersen (QALSODY; Biogen, Cambridg
- Wearable Sleep Monitor Receives Third FDA Clearancehttps://practicalneurology.com/news/wearable-sleep-monitor-receives-third-fda-clearance/2470144/Wesper (New York, NY) announced th
- New Nasal Spray Treatment for Migraine Approvedhttps://practicalneurology.com/news/new-nasal-spray-treatment-for-migraine-approved/2470137/The Food and Drug Administration (FDA) approved a new nasal spray for the treatment of acute migraine with or without aura in adults. Zavegepant (Zavzpret; Pfizer, New York, NY) represents the first intranasal-administered